Patient Impact
AtaiBeckley Patient Impact seeks to support and collaborate with non-profits and organizations who share our mission to create breakthroughs in mental health.
We collaborate with non-profit, mission-driven organizations advancing education, trust, access, community support, and responsible innovation. Please scroll down for more information on current and previous projects. If you would like to discuss opportunities for future collaborations, please get in touch at impact@ataibeckley.com
Patient Impact Grant Program
Meaningful progress in mental health requires more than scientific innovation - it needs patient insight, responsible education, community leadership and ecosystem-wide collaboration.
Launched in recognition of Mental Health Awareness Month 2026, the AtaiBeckley Patient Impact Grant Program supports non-profit, mission‑driven organizations whose work improves mental health outcomes through community leadership, education, and innovative research.
The program will award three grants of $20,000 each to causes working across the following areas:
- Community Support: Organizations who support equitable access to existing and emerging mental health treatments. Initiatives may focus on reducing barriers, building trust, and strengthening support for community‐led or culturally responsive approaches, particularly among underserved or historically excluded populations.
- Education & Stigma Reduction: Organizations who advance patient-centered education and public-facing initiatives that promote accurate understanding of mental health. Initiatives may focus on increasing awareness, reducing stigma, and fostering responsible engagement among patients and communities.
- Ecosystem Innovation & Independent Research: Organizations who drive ethical innovation in the mental health ecosystem. Initiatives may expand patient access, strengthen support systems, or develop patient-informed approaches that improve outcomes and community trust.
Who Should Apply?
Non-profits, charities, and mission-driven organizations working in: mental health support and access; mental health stigma reduction; community leadership and responsible public education around mental health; equity-focused initiatives in mental health; independent research on patient experience, ethics, or ecosystem needs within mental health (no investigational compounds).
Application Details
- Application Deadline: September 1st, 2026
- Grant recipients will be selected by a review panel comprised of Caroline Lilley, Head of Patient Impact at AtaiBeckley, and Kevin Craig, MD, Chief Medical Officer at AtaiBeckley, along with Dr. Jessica Jackson, Vice President of Alliance Development at Mental Health America (MHA). Dr. Jackson is participating as an external reviewer, and Mental Health America is not involved in administration of the broader grant program.
- Funding decisions are based on published criteria and recipient independence.
Our Commitment
This is an indication-agnostic charitable grant program. AtaiBeckley will not influence grantee content, strategy, or outputs and no data, insights, materials, messaging, or outputs generated by grantees will be used to inform AtaiBeckley’s strategy, operations or clinical development activities. AtaiBeckley will have no editorial control, content approval rights, or influence over grantee publications, messaging, advocacy positions, or research findings. Funding does not create any expectation of alignment with company viewpoints, public positions, or future business interests.
Clinical Research
We are working to develop rapid-acting, durable and scalable new treatment options for people living with difficult-to-treat mental health conditions. We are deeply grateful to the many participants who have already contributed to our research via clinical trials. Their involvement has been vital to advancing understanding of our investigational compounds and the patient experience.
Understanding the patient experience
As part of our BPL-003 studies, we closely monitored how people subjectively experience treatment with the compound in a clinical setting in order to better characterize the participant experience. These insights have informed how we prepare, support and care for participants before, during and after treatment.
The atai Fellowship Fund at Massachusetts General Hospital
The atai Fellowship at Massachusetts General Hospital’s (MGH) Center for the Neuroscience of Psychedelics was created to facilitate research into the potential of psychedelics to address unmet needs in mental health care and support promising graduate students in furthering their professional careers.
Across its 2022–2024 cohorts, the Fellowship has enabled research fellows to:
- Conduct clinical studies, including the first Investigational New Drug (IND) approved by the FDA' gastroenterology division for a study on psilocybin‑assisted therapy in irritable bowel syndrome, and a pilot study into the cardiovascular safety of repeated psychedelic use.
- Advance mechanistic science, from mapping serotonin receptors and neuroplasticity to investigating the role of endogenous DMT in the human brain.
- Develop neuroimaging and biomarker approaches to understand treatment responsiveness.
- Publish influential research, present at major scientific conferences, and secure competitive grants and career‑advancing opportunities, including joint PhD programs.
Partnering with Patients
We believe that people with lived experience of mental health conditions and of participating in clinical trials are essential partners in shaping the future of mental health treatments.
Patient Council
In 2023, Beckley Psytech created a Patient Council in partnership with The Psychedelic Participant Advocacy Network (PsyPAN). The Council included four patient experts with personal experience of living with mental health conditions and taking part in psychedelic clinical trials, along with three members of Beckley Psytech’s team who specialize in patient support and trial design.
Over a year, the Council held three workshops focused on the full trial journey—from signing up and preparing for treatment, to the experience itself and integration. Together, we identified areas where improvements could be made and developed suggestions to help others in the field. These insights were shared in a Patient Impact Report.
In recognition of the Patient Council project, and the collaboration between Beckley Psytech and PsyPAN, Beckley Psytech received the Silver Award in OVID Health's Patient Partnership Index (PPI) in 2023 and 2024. In 2026, AtaiBeckley received the Silver Award in the Patient Participant Index in collaboration with PsyPAN, in recognition of their joint efforts to strengthen participant partnership in psychedelic clinical research.
Post-Participant Peer Support Pilot Program
Beckley Psytech provided PsyPAN with funding for a peer support program. The 12-month pilot involved 20 UK-based participants who had taken part in a UK-based psychedelic clinical trial for a serious mental health illness.
Advocacy and Community Engagement
We are committed to working with partners to support fair access to innovative and effective mental health treatments. By working together, we believe we can drive more inclusive and impactful mental health solutions from research through to reality.
Mental Health America
In 2025, Beckley Psytech joined Mental Health America’s Regional Policy Council, a national network dedicated to shaping mental health policy through community, collaboration, and lived experience.